Drugs / AP-472
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07432958 | Feb 2026 → Sep 2027 expected | Parkinson disease | Appello Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AP-472 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07432958 ↗ |
| Route | Oral | “Oral tablet” NCT07432958 ↗ |